(beta-agonist/corticosteroid) is recommended as a means to streamline therapy in patients with persistent asthma. (Anon. 2005b; British Thoracic Society 2005). Ciclesonide is not available in a combination formulation and therefore patients would be required to have two separate inhalers. There is evidence that lung function improvements are maintained for up to 1 year of treatment. The impact of ciclesonide use on overall disease course, DALYs, and hospitalization rate as compared with other currently available inhaled corticosteroids has not been reported. These measures are important to the overall evaluation of the expected role of ciclesonide in the management of persistent asthma. References Adachi M, Miyamoto T, Masuda K, Sakai T. Equal or superior efficacy of ciclesonide 320 mcg or 640 mcg as compared with CFC-beclomethasone dipropionate 800 mcg in the treatment of patients with moderate to severe asthma. Poster presented at: American Thoracic Society Annual Meeting; May 21, 2006; San Diego, CA. Poster G25. Anon. Asmanex Twisthaler (package insert). Kenilsworth, NJ Schering Corporation; February 2005a. Anon. Global strategy for asthma management and prevention. Available at: http://www.ginasthma.com/guidelineitem.asp?l1=2&l2=1&intId=60 (accessed July 28, 2005b). Anon. Alvesco Prescribing Information. Available at: http://www.alvesco.com (accessed June 16, 2006). Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol. 2005;115:940–945. Bateman ED, Balint B, Bodzenta-Lukaszyk A, et al. Treatment of severe asthma using ciclesonide 160 mcg once daily or 320 mcg twice daily – a comparison. Poster presented at: American Thoracic Society Annual Meeting; May 23, 2006a; San Diego, CA. Poster K42. Bateman E, Karpel J, Casale T, Wenzel S, Banerji D. Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest. 2006b;129:1176–1187. Bateman ED, Langan J, Vereecken G, Smau L, Engelstätter R. Efficacy and tolerability of ciclesonide compared with fluticasone propionate in patients with moderate-to-severe asthma. Poster presented at: American Thoracic Society Annual Meeting; May 21, 2006c; San Diego, CA. Poster G23. Berger WE. Ciclesonide: a novel inhaled corticosteroid for the treatment of persistent asthma—a pharmacologic and clinical profile. Therapy. 2005;2:167–178. Bernstein D, Nathan R, Ledford D, et al. Ciclesonide, a new inhaled corticosteroid, significantly improves asthma-related quality of life in patients with severe, persistent asthma. J Allergy Clin Immunol. 2005;115:S210. Bernstein D, Caballero-Fonseca F, Zhang P, Lloyd M, Banerji D. Once-daily ciclesonide has no effect on hypothalamic-pituitary-adrenal-axis function in prepubertal children with mild, persistent asthma. J Allergy Clin Immunol. 2006;117(Suppl. 2):S184 (Abstract 715). Biberger C, von Behren V, Malek R, et al. Efficacy and safety of ciclesonide compared with budesonide in asthma patients: A randomized 12-week study. Abstract presented at: American Thoracic Society Annual Meeting; May 18, 2003; Seattle, WA. Abstract page A771. Boulet L-P, Drollman A, Magyar P, et al. Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med. 2006a;100:785–794. Boulet L-P, Hofbauer P, Voves R, Wolf S, Tiesler C, Engelstätter R. Efficacy and tolerability of ciclesonide (MDI) and fluticasone propionate (Diskus®) in patients with moderate asthma. Poster presented at: American Thoracic Society Annual Meeting; May 21, 2006b; San Diego, CA. Poster G24. Core Evidence 2006;1(4) Ciclesonide | place in therapy review Bousquet J, Bousquet PJ, Godard P, Daures J-P. The public health implications of asthma. Bull World Health Organ. 2005;83:548–554. British Thoracic Society, Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. Available at: http://www.enterpriseportal2.co.uk/filestore/bts/asthmaupdatenov05.pdf (accessed November 14, 2005). Buhl R, Vinkler I, Magyar P, et al. Once daily ciclesonide and twice daily fluticasone propionate are equally effective in the treatment of patients with asthma. Eur Respir J. 2004;24(Suppl. 48):346s (Abstract 2177). Buhl R, Vinkler I, Magyar P, et al. Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther. 2005a; November 23; [Epub ahead of print]. Buhl R, Wolf S, Tiesler C, et al. Once-daily ciclesonide is as effective as twice- daily fluticasone propionate in improving lung function in patients with mild-to- moderate persistent asthma. Poster presented at: American Thoracic Society Annual Meeting; May 23, 2005b; San Diego, CA. Poster G19. Chapman KR, Patel P, Boulet LP, et al. Efficacy and long-term safety of ciclesonide in asthmatic patients as demonstrated in a 52 week long study. Eur Respir J. 2002;20(Suppl. 38):373s (Abstract 2328). Chapman KR, Patel P, D'Urzo AD, et al. Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy. 2005;60:330–337. Crim C, Pierre L, Daley-Yates P. A review of the pharmacology and pharmacokinetics of inhaled fluticasone propionate and mometasone furoate. Clin Ther 2001;23:1339–1354. Derom E, Van De Velde V, Marissens S, Engelstätter R, Vincken W, Pauwels R. Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther. 2005;18:328–336. Dolovich MB, Ahrens RC, Hess DR, et al; American College of Chest Physicians; American College of Asthma, Allergy, and Immunology. Device selection and outcomes of aerosol therapy: evidence-based guidelines. Chest. 2005;127:335–371. Drollmann A, Nave R, Steinijans VW, Baumgartner E, Bethke TD. Equivalent pharmacokinetics of the active metabolite of ciclesonide with and without use of the AeroChamber PlusTM spacer for inhalation. Clin Pharmacokinet. 2006; 45:729–736. Dyer M, Halpin DMG, Stein K. Inhaled ciclesonide versus inhaled budesonide or inhaled beclomethasone or inhaled fluticasone for chronic asthma in adults: a systematic review. BMC Fam Pract. 2006;7:34. Engelstätter R, Escher A, Häfner D. Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide. Eur Respir J. 2005;1738:255s. Gauvreau GM, Boulet LR, Postma DS, et al. Effect of low-dose ciclesonide on allergen-induced responses in subjects with mild allergic asthma. J Allergy Clin Immunol. 2005;116:285–291. Gelfand EW, Georgitis JW, Noonan M, Ruff M. Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr. 2006;148:377–383. Gerth van Wijk R. Assessment of quality of life: advantages and pitfalls. Clin Exp Allergy Rev. 2005;5:32–35. Goeman DP, Aroni RA, Stewart K, et al. Patients’ views of the burden of asthma: a qualitative study. Med J Aust. 2002;177:295–299. Gupchup GV, Wolfgang AP, Thomas JI. Reliability and validity of the asthma quality of life questionnaire – marks in a sample of adult asthmatic patients in the United States. Clin Ther. 1997;19:1116–1204. Halpern MT, Khan ZM, Stanford RH, Spayde KM, Golubiewski M. Asthma: resource use and costs for inhaled corticosteroid vs leukotriene modifier treatment – a meta-analysis. J Fam Pract. 2003;52:382–389. Hansel TT, Benezet O, Kafé H, et al. A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther. 2006;28:906–920. Hübner M, Hochhaus G, Derendorf H. Comparative pharmacology, bioavailability, pharmacokinetics, and pharmacodynamics of inhaled glucocorticosteroids. Immunol Allergy Clin North Am. 2005;25:469–488. 247